2:1 for new genomic techniques
At the end of December, genetic engineering sceptics celebrated that the Council of Agriculture Ministers narrowly failed to reach a qualified...
Curve Therapeutics raises £40.5m in Series A financing
New investors Columbus Venture Partners and British Patient Capital and founding investor Advent Life Sciences as well as seed investor Epidarex...
Jazz Pharmaceuticals licences KRAS blocker from Redx Pharma
Under the term of the agreement, Redx Pharma plc (Alderley Park, UK) is to receive US$10m upfront and up to US$870m in milestone payments. Redx is...
EU parliament backs deregulation of New Genome Techniques
With the MEPs' approval of the amendments to the European Commission's draft legislation, the way is now clear for a regulation that distinguishes...
Vidac Pharma Holding plc reports preclinical proof of principle
Vidac Pharma Holdings plc will report promising results for its cancer drug candidate VDA-1275 in multiple mouse cancer and human cellular...
Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
PulseSight to disrupt AMD space
Aiming to address the pressing challenges of age-related macular diseases (AMD), including wet and dry AMD, along with geographic atrophy (GA),...